他拉唑帕尼(Talzenna/Talazoparib)中文说明书

【印度代购提示，本品适应症】

用于存在有害或疑似有害gBRCA突变、HER2-局部晚期或转移性乳腺癌成人患者的治疗。

【印度代购提示，本品作用机制】

聚（ADP-核糖）聚合酶（PARP）酶的抑制剂，包括PARP1和PARP2，它们在DNA修复中起作用。含有BRCA 1和2等DNA修复基因缺陷的癌细胞系的体外研究表明，塔拉唑巴诱导的细胞毒性可能涉及抑制PARP酶活性和增加PARP-DNA复合物的形成，导致DNA损伤、细胞增殖减少和细胞凋亡。在表达突变或野生型BRCA1和2的人类患者衍生的异种移植乳腺癌肿瘤模型中观察到他唑巴肽抗肿瘤活性。

Inhibitors of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2, which play a role in DNA repair. In vitro studies on cancer cell lines with defects in DNA repair genes such as BRCA 1 and 2 have shown that talazoba-induced cytotoxicity may involve inhibition of PARP enzyme activity and increased formation of PARP-DNA complex, leading to DNA damage, reduced cell proliferation, and apoptosis. Antitumor activity of tazobatide was observed in xenograft breast cancer tumor models derived from human patients expressing mutant or wild-type BRCA1 and 2.

【印度代购提示，本品药品规格】

印度代购提示，本品

0.25mg或1mg*30粒

【印度代购提示，本品副作用】

疲劳，贫血，恶心，中性粒细胞减少，头痛，血小板减少，呕吐，脱发，腹泻，食欲减退。最常见的实验室异常（≥25％）是：血红蛋白，血小板，中性粒细胞，淋巴细胞，白细胞和钙减少。葡萄糖，丙氨酸氨基转移酶，天冬氨酸氨基转移酶和碱性磷酸酶增加。

Fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, hair loss, diarrhea, loss of appetite. The most common laboratory abnormalities (≥ 25%) were: decreased hemoglobin, platelets, neutrophils, lymphocytes, white blood cells, and calcium. Increased glucose, alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase.

【印度代购提示，本品用法用量】

推荐剂量为1mg，每日一次，与食物或者不与食物同服；对于中度肾功能不全（CLcr 30-59mL/min）的患者，推荐的剂量为每日一次0.75mg。